		Within 28 days of enrolment	C1	C1	C1 D15	C2	prior to C3D1	C3 to C6	prior to C7D1	C7 to C12	prior to C13D1	C13 to C15	prior to C16D1	C16 to C21	prior to C22D1	C22 to C27	prior to C28D1	C28 to C33	prior to C34D1	C34 to C36	C37 to C39	prior to C40D1	C40 to C45	prior to C46D1	C46 to C51	prior to C52D1	C52 to C63	prior to C64D1	C64 to 75	prior to c76d1	c76 to 87	at the end of FU	at time of PD	every 6 months after TOP	via eMCL registry
Day(s) of assessment within cycle	Day(s) of assessment within cycle		D1	D8	D15	D1		D1 each		D1 each		D1 each		C16D1, C19D1		C22D1, C25D1		C28D1, C31D1		C34D1	C37D1		C40D1, C43D1		C46D1, C49D1		D1 of C52, C55, C58, C61		D1 of C64, C67, C70, C73		D1 of C76, C79, C82, C85				
Cycle length	Cycle length		21 days			21 days		21 days		21 days		28 days		28 days		28 days		28 days		28 days	28 days		28 days		28 days		28 days		28 days		28 days				
Approximate time from treatment start [months]	Approximate time from treatment start [months]						1,5		4,5		9		12		18		24		30			36		42		48		60		72		≤ 84			
Study treatment	Study treatment																																	
Obinutuzumab	Obinutuzumab		1000 mg d1,2*																															
Glofitamab	Glofitamab			2.5 mg	10 mg	30 mg (d1)		30 mg (d1 of each cycle)		30 mg (d1 of each cycle)																								

		Screening	Induction	Induction	Induction	Induction	First response assessment	Induction	Second response assessment	Induction	Third response assessment	Maintenance	Forth response assessment	Maintenance	fifth response assessment	Maintenance	sixth response assessment	Maintenance	seventh response assessment	Maintenance	Maintenance	eighth response assessment	Maintenance	ninth response assessment	Maintenance	tenth response assessment	Maintenance	eleventh response assessment	Maintenance	twelfth response assessment	Maintenance	End of Study Evaluation (EOS)	Time of Progression visit (TOP)	Survival Follow up	Long-term FU (registry)
		Within 28 days of enrolment	C1	C1	C1 D15	C2	prior to C3D1	C3 to C6	prior to C7D1	C7 to C12	prior to C13D1	C13 to C15	prior to C16D1	C16 to C21	prior to C22D1	C22 to C27	prior to C28D1	C28 to C33	prior to C34D1	C34 to C36	C37 to C39	prior to C40D1	C40 to C45	prior to C46D1	C46 to C51	prior to C52D1	C52 to C63	prior to C64D1	C64 to 75	prior to c76d1	c76 to 87	at the end of FU	at time of PD	every 6 months after TOP	via eMCL registry
Day(s) of assessment within cycle	Day(s) of assessment within cycle		D1	D8	D15	D1		D1 each		D1 each		D1 each		C16D1, C19D1		C22D1, C25D1		C28D1, C31D1		C34D1	C37D1		C40D1, C43D1		C46D1, C49D1		D1 of C52, C55, C58, C61		D1 of C64, C67, C70, C73		D1 of C76, C79, C82, C85				
Cycle length	Cycle length		21 days			21 days		21 days		21 days		28 days		28 days		28 days		28 days		28 days	28 days		28 days		28 days		28 days		28 days		28 days				
Approximate time from treatment start [months]	Approximate time from treatment start [months]						1,5		4,5		9		12		18		24		30			36		42		48		60		72		≤ 84			
Study treatment	Study treatment																																	
Obinutuzumab	Obinutuzumab		1000 mg d1,2*																															
Glofitamab	Glofitamab			2.5 mg	10 mg	30 mg (d1)		30 mg (d1 of each cycle)		30 mg (d1 of each cycle)																								
Pirtobrutinib continuously (Cohort A and HR Cohort B)	Pirtobrutinib continuously (Cohort A and HR Cohort B)		200 mg	200 mg	200 mg	200 mg		200 mg		200 mg		200 mg		200 mg		200 mg		200 mg		200 mg	200 mg		200 mg		200 mg		200 mg		200 mg		200 mg				
Pirtobrutinib continuously (SR Cohort B)	Pirtobrutinib continuously (SR Cohort B)		200 mg	200 mg	200 mg	200 mg		200 mg		200 mg		200 mg		200 mg		200 mg		200 mg		200 mg														
Mandatory hospitalization	Mandatory hospitalization			x	x	x																												
Assessments	Assessments																																	
Histological diagnosis of MCL	Histological diagnosis of MCL	x																																
Reference Pathology [2]	Reference Pathology [2]	x																																
Inclusion/ exclusion criteria [4]	Inclusion/ exclusion criteria [4]	x																																
Medical history [3]	Medical history [3]	x																													x	x		
Demographic data	Demographic data	x																																
Informed consent	Informed consent	x																																
EMCL-Registry [5]	EMCL-Registry [5]	x																																
Pregnancy test (fertile females only) [9]	Pregnancy test (fertile females only) [9]	≤ 7 days prior c1d1																										x						
Consideration of sperm cryo-preservation and suppression of ovulation	Consideration of sperm cryo-preservation and suppression of ovulation	x																																
Inclusion/ exclusion criteria [4]	Inclusion/ exclusion criteria [4]	x									x						x																	
Cardiac function evaluation (ECG, Echokardiography)	Cardiac function evaluation (ECG, Echokardiography)	x																																
Hepatitis/ HIV serology [11]	Hepatitis/ HIV serology [11]	x																																
MRI brain (if s/o brain involvement)	MRI brain (if s/o brain involvement)	x																																
Concomitant medication	Concomitant medication	x	x			x		x		x		x		x		x		x		x	x		x		x		x		x		x	x		
ECOG	ECOG	x	x	x	x	x		x		x		x		x		x		x		x	x		x		x		x		x		x	x		
Weight (+ height at screening)	Weight (+ height at screening)	x	x	x	x	x		x		x		x		x		x		x		x	x		x		x		x		x		x	x		
Vital signs (BP, HR, O2 Saturation, temperature)	Vital signs (BP, HR, O2 Saturation, temperature)	x	x	x	x	x		x		x		x		x		x		x		x	x		x		x		x		x		x	x		
Physical examination (A or B) [7]	Physical examination (A or B) [7]	A	A	B	B	B		B		B		B		B		B		B		B	B		B		B		B		B		B	A	A		
Blood draw (A, B, C or D) [10]	Blood draw (A, B, C or D) [10]	A	B	B	B	B		B		B		B		B		B		B		B	B		B		B		B		B		B	A	A		
IgG, IgA, IgM	IgG, IgA, IgM	x						C3D1		C7D1		C13D1		C16D1, C19D1		C22D1, C25D1		C28D1, C31D1		C34D1	C37D1														
PET/CT (including diagnostic CT of neck, thorax, abdomen, pelvis)	PET/CT (including diagnostic CT of neck, thorax, abdomen, pelvis)	x									x						x																	
CT scan (neck, thorax, abdomen, pelvis)	CT scan (neck, thorax, abdomen, pelvis)						x		x				x		x				x			x		x				x		x		x	x		
MRD peripheral blood 14	MRD peripheral blood 14	x					x		x		x		x				x					x				x (cohort B only)		x (cohort B only)						
2 x streck tubes (ctDNA) [20]	2 x streck tubes (ctDNA) [20]	x					x		x		x		x				x					x				x (cohort B only)		x (cohort B only)						
Bone Marrow Assessment 3	Bone Marrow Assessment 3	x									x						x															x		
MRD bone marrow 15	MRD bone marrow 15										x						x																	
In-depth immunophenotyping 16	In-depth immunophenotyping 16	x		x		x	x		x		x		x				x					x				x (cohort B only)		x (cohort B only)						
Antigen-specific T-cell responses (CMV/ SARS-COV2) 16	Antigen-specific T-cell responses (CMV/ SARS-COV2) 16	x									x						x																	
Serologic response (CMV / SARS-COV2)	Serologic response (CMV / SARS-COV2)	x									x						x																	
Plasma sampling for cytokines 11	Plasma sampling for cytokines 11	x	prior Obi	prior and after Glofit	24 h after Glofit	24 h after Glofit																												
Neurological assessment 18	Neurological assessment 18	x	x	x	x	x		x		x													x		x			x			x	x		
Safety	Safety																																	
Recording of AEs / SAEs 17	Recording of AEs / SAEs 17		x	x	x	x		x		x		x		x		x		x		x	x		x		x		x		x		x	x		
Secondary malignancies	Secondary malignancies		x	x	x	x		x		x		x		x		x		x		x	x		x		x		x		x		x	x		
FU in eMCL-Registry	FU in eMCL-Registry																																	x

For Patients in Survival Follow-Up, Salvage Therapy or Maintenance to be documented half-yearly from Time of Progression until end of Study